Amatsigroup, a European contract development and manufacturing organization (CDMO) located in France, has acquired Disposable-Lab, a French company specialized in manufacturing sterile injectable clinical batches.

Founded in 2008 in Martillac, Disposable-Lab says it benefited from a growing market demand for single-use solutions for the aseptic production of technical and clinical batches to support the development of targeted new therapies based on biological molecules—immunotherapy in oncology, vaccines, etc.—as well as non-conventional processes—sterile powder filling, gene therapy, active vaccines and very small batch sizes.

Disposable-Lab reported €2.2 million in revenues in 2016 with 15 employees.

Amatsigroup made the move to buy Disposable-Lab to extend its aseptic manufacturing solutions under Good Manufacturing Practices (GMP) compliant environment; increase its overall manufacturing capacity for sterile clinical batches further to a recent investment on a second manufacturing line at its Idron’s facility; and expand its footprint in the supply of clinical services.

“This acquisition fits perfectly with our strategy of being recognized as a leader in the field of sterile clinical batches manufacturing, matching perfectly the pharmaceutical industry increasing needs,” said Alain Sainsot, chairman, Amatsigroup.

“We are very proud to join forces with Amatsigroup, a key player in clinical batches supply to the pharmaceutical industry. By leveraging the close fit between our businesses and the expertise of our teams, we will be able to develop the best possible manufacturing process to meet our customers’ requirements,” said Jean-Pascal Zambaux, founder, Disposable-Lab.